IMNM:NASDAQImmunome, Inc. analysis

At $21.68, Immunome, Inc. shows no decisive moving-average alignment, leaving the trend neutral. Across the trailing 30 sessions it lost 20.3%. Momentum indicators put RSI at 33.4 (approaching oversold) with MACD reading bearish. The recent range runs from support at $20.84 up to resistance at $28.49.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 66.1% above the current price.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 54.0%, a beta of 1.67 and a maximum drawdown of 33.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
The horizons diverge: sell near-term but hold on a long view, at 3/10 conviction over the longer horizon.